|
Originally published In Press as doi:10.1074/jbc.M203002200 on April 23, 2002
J. Biol. Chem., Vol. 277, Issue 30, 27517-27527, July 26, 2002
Epidermal Growth Factor-mediated Activation of
the ETS Domain Transcription Factor Elk-1 Requires Nuclear Calcium*
Thomas
Pusl §,
Julie J.
Wu¶,
Tracy L.
Zimmerman ,
Lei
Zhang¶,
Barbara E.
Ehrlich¶,
Martin W.
Berchtold**,
Joannes B.
Hoek ,
Saul J.
Karpen ,
Michael H.
Nathanson , and
Anton M.
Bennett§§§
From the Department of Medicine, Yale University
School of Medicine, New Haven, Connecticut 06520, the ¶ Department
of Pharmacology, Yale University School of Medicine, New Haven,
Connecticut 06520, the Department of Pediatrics, Baylor College
of Medicine, Houston, Texas 77030, the ** Department of
Molecular Cell Biology, University of Copenhagen, 1353 Copenhagen,
Denmark, and the  Department of Pathology,
Anatomy and Cell Biology, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107
Received for publication, March 28, 2002
 |
ABSTRACT |
Cytosolic and nuclear Ca2+ have
been shown to differentially regulate transcription. However, the
impact of spatially distinct Ca2+ signals on
mitogen-activated protein kinase-mediated gene expression remains
unknown. Here we investigated the role of nuclear and cytosolic
Ca2+ signals in epidermal growth factor
(EGF)-induced transactivation of the ternary complex factor Elk-1 using
a GAL4-Elk-1 construct. EGF increased Ca2+ in both the
nucleus and cytosol of HepG2 or 293 cells. Pretreatment with the
intracellular Ca2+ chelator
bis(2-aminophenyl)ethyleneglycol-N,N,N',N'-tetraacetic acid significantly reduced EGF-induced transactivation of Elk-1, indicating that EGF-stimulated Elk-1 transcriptional activity is
dependent on intracellular Ca2+. To determine the relative
contribution of nuclear and cytosolic Ca2+ signals during
EGF-mediated Elk-1 transactivation, Ca2+ signals in either
compartment were selectively impaired by targeted expression of the
Ca2+-binding protein parvalbumin to either the nucleus or
cytosol. Suppression of nuclear but not cytosolic Ca2+
signals inhibited EGF-induced transactivation of Elk-1. However, suppression of nuclear Ca2+ signals did not affect the
ability of ERK either to become phosphorylated or to undergo
translocation to the nucleus in response to EGF. Elk-1 phosphorylation
and nuclear localization following EGF stimulation were also unaffected
by suppressing nuclear Ca2+ signals. These results suggest
that nuclear Ca2+ is required for EGF-mediated
transcriptional activation of Elk-1 and that phosphorylation of Elk-1
alone is not sufficient to induce its transcriptional activation in
response to EGF. Thus, subcellular targeting of parvalbumin reveals a
distinct role for nuclear Ca2+ signals in mitogen-activated
protein kinase-mediated gene transcription.
 |
INTRODUCTION |
Ca2+ is a fundamental second messenger that mediates a
range of biological processes, including fertilization, mitogenesis, exocytosis, synaptic plasticity, gene expression, differentiation, proliferation, and apoptosis (1-9). Although it is not completely established how Ca2+ coordinates such diverse effects, both
the amplitude and frequency of Ca2+ signals have been shown
to contribute to its specificity (10-12). Further specificity of
Ca2+ signaling is achieved through differences in signaling
in discrete subcellular compartments (9, 13-15). For example, separate
machinery may be involved for regulating nuclear Ca2+
(Ca )1
and cytosolic Ca2+ (Ca )
(16-20). Moreover, Ca is required
for transcription via the cAMP response element (21) and
regulation of cAMP response element-binding protein-binding protein
activity (22), whereas Ca activates
transcription through the serum response element (21). Thus, spatially
distinct Ca2+ signals have distinct cellular effects.
Although our understanding of the distinct roles of both
Ca and
Ca in gene expression is limited,
it is well established that protein phosphorylation in the nucleus by
the mitogen-activated protein kinases (MAPK) is critical for gene
regulation (23, 24). Following phosphorylation by the MAPK kinases
(MKKs), the extracellular signal-regulated kinases 1 and 2 (ERKs),
c-Jun amino-terminal kinases, and p38 MAPKs each translocate to the
nucleus (25) where they transactivate various transcription factors by
serine and threonine phosphorylation (23, 24). Subsequently, these transcription factors direct transcriptional activation of genes that
are essential for the initiation of numerous physiological responses
such as mitogenesis, differentiation, and apoptosis (26-29). For
example, epidermal growth factor (EGF) receptor stimulation results in
nuclear accumulation of activated ERK, where it binds to and
phosphorylates the ETS domain-containing transcription factor Elk-1
(23, 30, 31). Phosphorylation of Elk-1 is thought to increase its
transcriptional activity, leading to the transcription of
growth-related proteins, most notably c-Fos (32, 33). In addition to
ERK activation, EGF and other growth factors raise intracellular free
Ca2+ levels by activating phospholipase C with
subsequent formation of inositol 1,4,5-trisphosphate (34-36).
Ca2+ modulates several signaling pathways that converge at
various points to regulate Elk-1 transcriptional activity. Work from
several groups demonstrates that growth factor- and cytokine-induced
increases in Ca2+ contribute to the activation of the
ERK/Elk-1 pathway via mechanisms that involve activation of signaling
components such as the Src-like kinases, Pyk2, and the
Ca2+-sensitive Ras guanine nucleotide-releasing factor
(37-39). In addition, growth factor-induced Ca2+ increases
lead to activation of other pathways such as the
Ca2+/calmodulin-dependent protein kinases that
also participate in the regulation of Elk-1 (40-43). In contrast to
the positive signaling role of Ca2+ in growth
factor-mediated Elk-1 activation, Ca2+ has been proposed to
play also a negative role in Elk-1 regulation by growth factors.
Following stimulation the ERK, c-Jun amino-terminal kinase, or p38 MAPK
activation of Elk-1 is inhibited by the phosphatase calcineurin (44,
45). Thus, growth factor-mediated changes in Ca2+ can lead
to the regulation of Elk-1 via multiple pathways in both positive and
negative manners. The distinct actions of Ca2+ when
localized to either the nucleus or cytosol might provide some
explanation for the complexity of Elk-1 regulation in growth factor
signal transduction.
In this study we have investigated the relative contribution of both
Ca and
Ca to the regulation of
MAPK-mediated gene expression in response to stimulation with EGF by
selective targeting of the Ca2+ chelator protein
parvalbumin (PV) to either the cytosol or the nucleus. Using this
novel approach, we have demonstrated that Ca but not
Ca is required for Elk-1
transcriptional activation in response to EGF stimulation.
 |
EXPERIMENTAL PROCEDURES |
Cells and Cell Culture--
HepG2, SK-HEP-1, 293, and COS cell
lines were cultured at 37 °C in 5% CO2 in Dulbecco's
modified Eagle's medium (Invitrogen) containing 10% fetal bovine
serum (Sigma), 1 mM sodium pyruvate (Invitrogen), 50 units/ml penicillin (Sigma), and 50 µg/ml streptomycin (Sigma).
Generation of Targeted Parvalbumin Expression
Constructs--
The nuclearly targeted PV expression vector was
constructed by subcloning a SalI/NotI fragment
representing the full-length rat PV cDNA in-frame into the
pCMV-Myc-Nuc vector (Invitrogen). This construct resulted in an
in-frame fusion of PV with a Myc epitope and a triplet sequence
representing the nuclear localization sequence derived from SV40 and
was designated pCMV-PV-Myc-Nuc. To generate a GFP fusion of
pCMV-PV-Myc-Nuc, the GFP coding sequence was PCR-amplified from
pCMV-Myc-Cyto-GFP (Invitrogen) using the primers 5'-AT AAG AAT GCG GCC
GCA ATG GCT AGC AAA GG-3' and 5'-A TAA GAA TGC GGC CGC TTT GTA GAG CTC
ATC-3', which resulted in the introduction of 5' and 3' NotI
sites. The PCR product was digested with NotI and subcloned
into pCMV-PV-Myc-Nuc to yield an in-frame GFP fusion
(pCMV-PV-GFP-Myc-Nuc). The final resulting fusion protein was
designated PV-NLS-GFP.
The cytoplasmically targeted PV expression vector was constructed by
subcloning the same SalI/NotI fragment of
full-length rat PV cDNA into the pCMV-Myc-Cyto vector (Invitrogen),
as described for pCMV-Myc-Nuc. This construct was designated
pCMV-PV-Myc-Cyto and was then used to generate a GFP fusion with PV.
GFP was subcloned in-frame at the carboxyl terminus of PV using the
GFP-specific primers described above. Next, the SalI site
was removed from the plasmid backbone by in vitro
mutagenesis using the QuikChange mutagenesis procedure as described by
the manufacturer (Stratagene, La Jolla, CA). The complete coding region
of the PV-GFP-Myc fusion protein was amplified using oligonucleotide
primers (5'-GGG GTC GAC GCA TTA CAA AAA AAA TTA GAA GAA TTA GAA TTA GAT
GAA ATG TCG ATG ACA GAC-3' and 5'-GCG AGC TTC TAG ACT ATG CGG CCC C-3')
to introduce the nuclear exclusion signal (NES) sequence derived from the MKK1 (46, 47). The NES sequence derived from MKK1 with this PV
fusion encoded a short stretch of amino acids that represent residues
32-44 of MEK1, which does not contain the putative ERK binding site.
These primers also introduced SalI and XbaI sites, which were used to subclone this DNA fragment into pCMV-Myc-Cyto to generate PV-NES-GFP.
Site-directed mutagenesis was carried out to generate the mutant
parvalbumins PV-NLS-CD-GFP and PV-NLS-CDEF-GFP coding for proteins in
which either one or both of the functional Ca2+-binding
sites (CD or EF domain) were inactivated by substituting a glutamate
for a valine residue at position 12 of each Ca2+-binding
loop (48). The PV-NLS-GFP DNA was used as a template for mutagenesis.
The following synthetic oligonucleotides containing mismatches in codon
62 of the CD loop or in codon 101 of the EF loop were used:
CD62, 5'-GC TTC ATT GAG GAG GAT GTG CTG GGG TCC ATT CTG-3', and EF101, 5'-GGC AAG ATT GGG GTT GAA
GTG TTC TCC ACT CTG GTG GCC-3' (mutated residues are
underlined). The sequences of PV-NLS-CD-GFP and PV-NLS-CDEF-GFP were
confirmed by automated DNA sequencing.
Cytosolic and Nuclear Ca2+ Measurements--
Two
types of Ca2+ measurements were made. Base-line
measurements of Ca and
Ca were performed with the
ratiometric Ca2+ indicators indo-1 and fura-2. Measurements
of agonist-induced changes in Ca
and Ca over time were performed
with rhod-2, fura-2, or fluo-4. In preparation for all experiments,
cells were plated onto glass coverslips and transfected 48 h in
advance with PV-NLS-GFP, PV-NES-GFP, or PV-NLS-CD-GFP. The cells were
loaded with 5-6 µM of the acetoxymethyl (AM) forms of
the respective indicators (Molecular Probes, Eugene, OR) for 30-60 min
at 37 °C. Indo-1-loaded cells were studied by two-photon microscopy,
and rhod-2- or fluo-4-loaded cells were studied using confocal
microscopy. A Bio-Rad MRC-1024 combined confocal and two-photon
microscope was used for both of these experiments. Fura-2 fluorescence
was observed by epifluorescence microscopy using a charge-coupled
device camera connected to a PC-based imaging system for analysis of
ratio measurements (Spectralyzer, Thomas Jefferson University,
Fluorescence Imaging Laboratory, Philadelphia, PA or Axon Imaging
Workbench, Axon Instruments, Foster City, CA).
For two-photon imaging, a femtosecond-pulsed Tsunami Ti:Sapphire laser
(Spectra-Physics, Mountain View, CA) was used as described previously
(49). Here, two-photon microscopy was used to excite the dual
wavelength Ca2+-sensitive fluorescent indicator indo-1 (50,
51). Indo-1-loaded cells were transferred to a chamber on the stage of
a Zeiss Axiovert microscope, which used a 63 × 1.4 N.A. oil
immersion objective, and the cells were perfused with a Hepes-buffered
solution. The Ti:Sapphire laser was tuned to a wavelength of 720 nm,
which is optimal for two-photon excitation of indo-1 (51). Emission
signals were detected at two wavelengths (360-430 and 445-505 nm)
using custom-made external photomultiplier tube detectors (Multiphoton Peripherals, Ithaca, NY). The images were generated from the ratio of
the lower wavelength image divided by the higher wavelength image.
Time lapse confocal imaging was performed as described previously (52).
Ca2+ transients were evoked by perfusing with buffer
containing 10 µM ATP or 0.25 µM ionomycin.
Cells loaded with the single wavelength Ca2+ dye rhod-2
(53) were first excited with the 488-snm line of a 15 mW krypton/argon
laser to detect GFP fluorescent cells and subsequently with the 568-nm
line to monitor rhod-2 fluorescence in these and nearby control cells.
The emitted light was collected at 522/30 nm and 605/30 nm,
respectively. The regions of interest were simultaneously monitored
within the nucleus and cytoplasm of transfected and untransfected
control cells in the same field and followed over time using Bio-Rad
Timecourse software. The fluorescence intensity was displayed as
arbitrary units, from which background fluorescence intensity was
subtracted. The amplitude of an evoked response was defined as the
difference between the peak and base-line fluorescence. Most of the
variability affecting fluorescent image intensity (uneven dye loading,
leakage of dye, photobleaching, and differences in machine settings)
was eliminated by comparing transfected cells only to untransfected
controls in the same field.
For the experiments involving fura-2, the fluorescent images were
obtained alternately at 340- and 380-nm excitation wavelengths with an
emission wavelength of 460 to 640 nm. After correction for background
fluorescence, Ca2+ transients in both nucleus and cytosol
of individual cells were expressed as the 340/380 nm fluorescence ratio.
Immunofluorescence--
For parvalbumin immunofluorescence, the
cells were methanol-fixed and co-labeled with propidium iodide. For
triple labeling experiments, 293 cells were serum-starved for 24-48 h
and then left unstimulated or treated with 100 ng/ml EGF for 15 min
prior to fixation in 4% paraformaldehyde. After blocking in
phosphate-buffered saline containing 3% bovine serum albumin, the
cells were incubated with primary antibodies for at least 2 h or
overnight. The primary antibodies used were polyclonal
anti-phospho-Elk-1 (1:100; Cell Signaling, Beverly, MA) and polyclonal
anti-phospho-pERK1/2 (1:100; Cell Signaling). Monoclonal antibodies to
the HA (1:1000) and FLAG (10 µg/ml) epitopes were obtained from
Covance (Princeton, NJ) and Sigma, respectively. Primary antibodies
were detected by incubation with Cy3-conjugated anti-rabbit IgG and
Cy5-conjugated anti-mouse IgG from Jackson ImmunoResearch (West Grove, PA).
Analysis of ERK Activation and Elk-1 Phosphorylation--
To
determine the phosphorylation status of ERK, 293 cells were transiently
transfected with 1 µg of pCG-HA-ERK2, and either 9 µg of
pCMV-Myc-Cyto-GFP (GFP), 6 µg of PV-NLS-GFP, 9 µg of PV-NES-GFP, 9 µg of PV-NLS-CD-GFP, or 6 µg of pMT2-H-Ras (V12) as indicated. 293 cells were either left unstimulated or stimulated with 10 ng/ml EGF for
the indicated times. The cells were washed twice with ice-cold
phosphate-buffered saline and lysed in 1 ml of Nonidet P-40 lysis
buffer (1.0% Nonidet P-40, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM
phenylmethylsulfonyl fluoride, 1 mM benzamidine, 2 mM NaVO3, and 50 mM NaF). The cell
lysates were cleared by centrifugation at 4 °C at 14,000 rpm for 10 min. The protein concentration was determined using Coomassie protein
reagent (Pierce). Approximately 0.5-1 mg of cell lysates were
incubated overnight with 5 µg of anti-HA monoclonal antibody (Roche
Molecular Biochemicals), and the immune complexes were collected on
protein A-Sepharose for 1 h. The immune complexes were washed
twice with 500 µl of ice-cold Nonidet P-40 lysis buffer (containing 2 mM NaVO3 and 5 mM NaF), followed by
two washes with 500 µl of ice-cold ST buffer (150 mM NaCl
and 50 mM Tris-HCl, pH 8, containing 2 mM
NaVO3 and 5 mM NaF). The immune complexes were
resolved by SDS-PAGE, and the proteins were transferred to Immobilon-P
membranes (Millipore, Bedford, MA) and immunoblotted with
anti-phospho-ERK and anti-ERK1/2 antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA).
The effects of Elk-1 phosphorylation were determined by transiently
transfecting 293 cells with 1 µg of Elk-1-FLAG (kindly provided by
Dr. Andrew Sharrocks, University of Manchester, Manchester, UK), and 5 µg of GFP, 3 µg of PV-NLS-GFP, 5 µg of PV-NES-GFP, 5 µg of
PV-NLS-CD-GFP, or 3 µg of H-Ras (V12) as indicated. GFP was used as
filler DNA to normalize the total amount of transfected DNA. The cells
were then either left unstimulated or stimulated with 10 ng/ml EGF or
0.25 µM ionomycin for the indicated times, washed twice
with ice-cold phosphate-buffered saline, and lysed in 500 µl of 1×
sample buffer. The cell lysates were resolved by SDS-PAGE, transferred
to Immobilon-P membranes, and subjected to immunoblotting with
anti-phospho(Ser383)-Elk-1 (Cell Signaling) and anti-FLAG
(Sigma) antibodies. Immunoblots were controlled for protein loading by
Ponceau S staining of transferred proteins on the Immobilon membrane.
Primary antibodies were detected using peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (Amersham Biosciences).
Elk-1 Transactivation Assay--
Elk-1 luciferase activity was
measured using a luciferase assay system kit from Promega (Madison, WI)
according to the manufacturer's instructions. 293 or HepG2 cells were
co-transfected with 0.5 µg of Elkc-GAL4 (Elkc), 0.5 µg of
5X-GAL4-Luc, 0.5 µg of SV-40 -galactosidase, and either 5 µg of
GFP, 3 µg of PV-NLS-GFP, 5 µg of PV-NES-GFP, or 5 µg of
PV-NLS-CD-GFP as indicated. Serum-starved 293 cells were left
unstimulated or were stimulated with either 10 ng/ml EGF or 0.25 µM ionomycin for 5 h. HepG2 cells were stimulated with either 100 ng/ml EGF or 0.5 µM ionomycin for 4 h. To determine the requirement of intracellular Ca2+ for
EGF-induced Elk-1 transactivation, HepG2 cells were transfected with
0.5 µg of Elkc, 0.5 µg of 5X-GAL4-Luc, 0.5 µg of SV-40
-galactosidase, and 3 µg of GFP. The cells were pretreated with
either vehicle control (Me2SO) or BAPTA-AM (30 µM) (Molecular Probes) for 20 min prior to stimulation
with 100 ng/ml EGF for 4 h. Luciferase and -galactosidase
activities were determined, and the luciferase values were normalized
to -galactosidase.
Statistical Analysis--
The data are given as the mean
values ± S.E. Groups of data were compared using one-way repeated
measures analysis of variance or one-way analysis of variance. When
significant overall effects were found, post-test comparisons between
selected groups were made using the Bonferroni multiple comparison
tests. A p value of <0.05 was considered to indicate
statistically significant differences. Statistical analyses were
performed with the PRISM statistical software program (GraphPad, San
Diego, CA).
 |
RESULTS |
Expression and Subcellular Localization of Targeted Parvalbumin-GFP
Fusion Proteins--
Previous experiments designed to selectively
block Ca2+ signaling in the nucleus have utilized
microinjection techniques to deliver a nondiffusible Ca2+
chelator into this subcellular compartment (21, 22). We took an
alternative approach to block Ca2+ in distinct subcellular
compartments by using the Ca2+-binding protein PV fused to
targeting sequences that direct its subcellular localization to
either the nucleus or cytosol. Although PV has been
demonstrated to inhibit Ca2+ signaling when expressed in
mammalian cells (54, 55), targeted expression of PV to discrete
subcellular compartments to locally buffer Ca2+ has not
been reported. Nuclear expression of PV was established by generating
an in-frame fusion of PV with the nuclear localization signal derived
from the SV40 large T antigen (56) (Fig.
1A). Cytosolic expression of
PV was established by generating a fusion protein of PV with the NES
derived from the MKK1 (46, 47) (Fig. 1A). Subcellular
localization and expression of the nuclear and cytosolically targeted
PV proteins were detected by fusion with GFP. Immunoblotting for PV in
PV-NLS-GFP and PV-NES-GFP COS-1 transfectants confirmed expression of
the appropriate molecular weight PV fusion proteins, whereas controls
showed no immunoreactivity (Fig. 1B). Confocal imaging of
PV-NLS-GFP- and PV-NES-GFP-transfected HepG2 cells verified nuclear and
cytoplasmic localization of PV-NLS-GFP and PV-NES-GFP proteins,
respectively (Fig. 1C).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Expression and subcellular localization of
targeted PV-GFP fusion proteins. A, schematic
representation of the targeted PV-GFP expression vectors. Rat PV
cDNA was fused to a targeting signal (NLS or NES), GFP, and
the c-Myc epitope (Myc). B, immunoblotting
of PV-GFP constructs. COS cells were transfected with expression
vectors for PV-NLS-GFP, PV-NES-GFP, or vector control (GFP). Total
cellular proteins were separated on SDS-PAGE and immunoblotted with a
monoclonal anti-PV antibody. PV-NLS-GFP and PV-NES-GFP direct
expression of the ~40-kDa fusion proteins. C,
subcellular localization of the indicated PV-GFP constructs using
confocal microscopy. Green indicates GFP, red
indicates the nuclear stain propidium iodide, and yellow
indicates co-localization of the two signals. Expression of PV-NLS-GFP
is restricted to the nucleus, whereas PV-NES-GFP is uniformly
distributed throughout the cytosol but excluded from the nucleus.
|
|
Targeted PV as a Selective Buffer of
Ca and
Ca --
To
determine whether targeted PV selectively buffers
Ca2+ in either the nucleus or cytosol, we examined the
effects of PV expression on ATP-induced Ca2+ increases in
both the nucleus and cytosol of HepG2 cells. ATP elicits a robust
increase in intracellular free Ca2+ via activation of
purinergic P2Y receptors and subsequent inositol 1,4,5-trisphosphate
formation (57, 58). Ca and
Ca were detected with the long wavelength indicator dye rhod-2 to avoid interference from GFP fluorescence. HepG2 cells expressing PV-NLS-GFP were stimulated with
ATP (10 µM), which increased rhod-2 fluorescence to
similar levels in the cytosol of both PV-NLS-GFP-transfected and
untransfected HepG2 cells (Fig. 2,
A, left panel, and C). However,
ATP-induced increases in nuclear fluorescence were reduced in
PV-NLS-GFP-transfected HepG2 cells, as compared with the increases in
nuclear fluorescence observed in untransfected control cells (Fig. 2,
A, right panel, and C;
n = 44, p < 0.01). In contrast,
expression of PV-NES-GFP suppressed ATP-induced increases in rhod-2
fluorescence in the cytosol relative to untransfected controls
(n = 31, p < 0.001) but did not affect
the rise in the nucleus (Fig. 2, B and C). Expression of GFP alone had no effect on ATP-induced Ca2+
signals (data not shown). These results demonstrate that expression of
PV in either the nucleus or cytoplasm selectively suppresses agonist-induced Ca2+ transients in the targeted cellular
compartment.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
ATP-induced increases in
Ca or Ca are selectively
blocked in HepG2 cells expressing either PV-NLS-GFP or PV-NES-GFP.
A, PV-NLS-GFP attenuates ATP-induced increases in
Ca but not
Ca . HepG2 cells expressing
PV-NLS-GFP along with untransfected controls were loaded with rhod-2
and stimulated with ATP (10 µM). Similar increases in
rhod-2 fluorescence were observed in the cytosol of the transfected and
untransfected cell (left panel). A large, rapid increase in
nuclear rhod-2 fluorescence was observed in the untransfected cell,
whereas the increase in nuclear fluorescence was markedly attenuated in
a nearby cell expressing PV-NLS-GFP (right panel).
B, PV-NES-GFP attenuates ATP-induced increases in
Ca but not
Ca . HepG2 cells expressing
PV-NES-GFP along with untransfected controls were loaded with rhod-2
and stimulated with ATP (10 µM). ATP-induced increases in
cytosolic rhod-2 fluorescence were markedly reduced in the
PV-NES-GFP-transfected cell (left panel). Similar increases
in rhod-2 fluorescence were observed in the nucleus of the transfected
and a nearby untransfected control cell (right panel).
C, summary of rhod-2 measurements. The data represent the
means ± S.E. of the increase in fluorescence
( F = Fmax Fbaseline) observed in 44 cells expressing
PV-NLS-GFP and 31 cells expressing PV-NES-GFP, plus 1-7 control cells
in the same field. The asterisks indicate significant
differences compared with untransfected controls.
|
|
In addition to agonist-induced Ca2+ signals, base-line
measurements using the ratiometric Ca2+ indicators indo-1
or fura-2 were performed. To avoid potential interference of the GFP
fluorescence with fura-2 and indo-1 fluorescence, we used PV-NLS
instead of PV-NLS-GFP. The cells were co-transfected with red
fluorescent protein, because this fluorophore is compatible with the
use of these fluorescent dyes and thus let us distinguish the
transfected cells from untransfected control cells. Basal levels of
Ca2+ in the nucleus were not significantly lower in cells
expressing PV-NLS cells, relative to PV-negative control cells (Fig.
3; n = 10, p = 0.39). These results were confirmed using indo-1
and two-photon imaging (data not shown).

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 3.
Basal Ca is unaffected
in cells expressing PV-NLS. Control SK-HEP-1 cells and cells
co-transfected with PV-NLS and red fluorescent protein were loaded with
fura-2 and analyzed by fluorescence ratio imaging. The data represent
the means ± S.E. obtained from 10 cells expressing PV-NLS and 25 PV-negative control cells.
|
|
EGF-mediated Elk-1 Transactivation Requires Intracellular
Ca2+--
Engagement of the EGF signaling pathway results
in the activation of ERK and subsequent transactivation of the ETS
domain-containing transcription factor Elk-1 (23). To determine the
requirement for Ca2+ in EGF-mediated activation of Elk-1,
total free cellular Ca2+ was buffered using the
intracellular Ca2+ chelator BAPTA-AM. To assess the ability
of EGF to induce Elk-1 transactivation, we utilized a chimera
representing the carboxyl terminus of Elk-1 (amino acids 307-428)
fused to the DNA-binding domain of the GAL4 transcription factor.
Previously, it has been shown that this Elk-1-GAL4 chimera undergoes
MAPK-induced phosphorylation and leads to the transcriptional
activation of a luciferase reporter driven by five GAL4 DNA-binding
element repeats (5X-GAL4-Luc) (32). HepG2 cells were co-transfected
with Elkc-1-GAL4 (Elkc), 5X-GAL4-Luc, and -galactosidase as a
control. These transfected cells were serum-starved for 48 h.
Prior to EGF stimulation, transfected HepG2 cells were pretreated for
20 min with either Me2SO (control condition) or BAPTA-AM
(30 µM) to chelate intracellular Ca2+. HepG2
cells were subsequently stimulated with EGF (100 ng/ml) for 4 h,
and the activity of Elk-1-mediated luciferase activity was determined.
These data showed that EGF-mediated Elk-1 transactivation was induced
1.6-fold relative to unstimulated HepG2 cells (Fig. 4). However, in HepG2 cells pretreated
with BAPTA-AM, the ability of EGF to induce Elk-1 transactivation was
completely inhibited (Fig. 4; p < 0.001). These
results demonstrate that intracellular Ca2+ is required for
EGF-induced Elk-1 transactivation in HepG2 cells.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 4.
EGF-induced Elk-1 transactivation in HepG2
cells is dependent upon intracellular Ca2+. HepG2
cells were rendered quiescent by serum deprivation and were pretreated
with either 30 µM BAPTA-AM or dimethyl sulfoxide
(DMSO) vehicle control for 20 min prior to EGF (100 ng/ml)
stimulation for 4 h. The lysates were prepared from these cells,
and the activities of luciferase and -galactosidase were determined.
The data shown represent the fold change in Elk-1 transactivation
relative to that of the unstimulated vector control, derived from the
normalized luciferase to -galactosidase activities. The results
represent the means ± S.E. from five separate experiments
performed in triplicate. The asterisk indicates a
significant difference (p < 0.001) compared with
EGF-stimulated DMSO control.
|
|
EGF-mediated Elk-1 Transactivation Requires Nuclear but Not
Cytosolic Ca2+--
EGF is known to mobilize
Ca2+ from intracellular Ca2+ stores by
activation of phospholipase C and subsequent inositol
1,4,5-trisphosphate formation in primary hepatocytes (59) and also in
several cell lines including A431 human epidermoid carcinoma (36) and
renal epithelial cells (60). To determine whether EGF induces
Ca2+ signals in both the cytosol and nucleus of HepG2
cells, serum-deprived cells loaded with fura-2 were stimulated with
50-60 ng/ml EGF, and changes in Ca
and Ca were monitored by
epifluorescence microscopy ratio imaging. Fig. 5A shows a typical
Ca2+ response in the two compartments during EGF
stimulation. It is clear that EGF induced significant increases in both
Ca and
Ca .

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of PV-NLS-GFP inhibits EGF-induced
Elk-1 transactivation in HepG2 cells. A, EGF increases
Ca2+ in both the nucleus and cytosol of HepG2 cells. HepG2
cells loaded with fura-2 were stimulated with 50-60 ng/ml EGF, and the
EGF-induced Ca2+ responses in the nuclear and cytosolic
compartment were monitored by epifluorescence microscopy ratio imaging.
The data shown are representative results from >10 cells.
B, HepG2 cells were transfected with either GFP (vector
control), PV-NLS-GFP, or PV-NES-GFP and were serum-deprived for 48 h prior to stimulation with EGF (100 ng/ml) for 4 h. The data
shown represent the fold change in Elk-1 transactivation relative to
that of the unstimulated vector control, derived from the normalized
luciferase to -galactosidase activities. The results represent the
means ± S.E. from five separate experiments performed in
triplicate. The asterisk indicates a significant difference
(p < 0.05) compared with EGF-stimulated GFP
control.
|
|
To determine the relative contribution of
Ca and
Ca to EGF-mediated Elk-1
transactivation, we utilized the targeted PV constructs. HepG2 cells
were co-transfected with a control vector (GFP), PV localized to the
nucleus (PV-NLS-GFP), or PV localized to the cytosol (PV-NES-GFP),
along with Elkc, 5X-GAL4-Luc, and -galactosidase. HepG2 cells were
serum-starved for 48 h and were then restimulated with EGF (100 ng/ml) for 4 h. As observed previously (Fig. 4), EGF stimulation
of HepG2 cells resulted in a 2-fold increase in Elk-1 transactivation
(Fig. 5B). However, EGF-induced Elk-1 transactivation was
completely inhibited in HepG2 cells that expressed PV-NLS-GFP (Fig.
5B; p < 0.05). In contrast, buffering the
cytosolic pool of Ca2+ with PV-NES-GFP did not exhibit any
appreciable diminution in the ability of EGF to activate Elk-1
(p > 0.05). These data demonstrate that targeted
expression of PV to the nucleus, but not the cytosol, inhibits
EGF-induced Elk-1 transactivation (Fig. 5B). Taken together with the experiments in Fig. 4, these data strongly suggest that nuclear Ca2+ is required for the appropriate
transactivation of Elk-1 in response to EGF in HepG2 cells.
Generation of a Nuclear Localized Ca2+-binding
Deficient Mutant of Parvalbumin--
To determine whether the
inhibitory effects of expressing PV in the nucleus specifically are due
to its Ca2+ buffering capacity, a nuclear localized mutant
form of PV that has reduced Ca2+ buffering capacity was
generated. Site-directed mutagenesis was used to inactivate either one
or both of the Ca2+-binding sites in the paired EF hand
sites of this protein (61). PV-NLS-CD-GFP contained an E62V
substitution in the CD Ca2+-binding site but maintained an
active EF Ca2+-binding site. The double mutant
PV-NLS-CDEF-GFP, containing E62V/E101V substitutions, was engineered to
inactivate both CD and EF sites. Because these mutations might affect
the ability of the parvalbumin antibody to recognize its epitope, the
monoclonal 9E10 c-Myc antibody was used to detect the tagged fusion
proteins. Immunoblotting of wild-type and mutated PV constructs in
SK-HEP-1 cell transfectants showed that expression of PV-NLS-CD-GFP was
reduced compared with wild-type PV-NLS-GFP, whereas the doubly
defective mutant PV-NLS-CDEF-GFP showed little or no detectable
expression (Fig. 6A). Ideally, the mutant of PV that was completely crippled in its
Ca2+-binding capacity would have been the most appropriate
control. However, as a result of the poor expression of this mutant,
the single Ca2+-binding site defective PV mutant was used
for subsequent studies. Confocal immunofluorescence confirmed the
nuclear localization of PV-NLS-CD-GFP (Fig. 6B).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 6.
Expression and subcellular localization of
Ca2+ binding-deficient PV mutants. A,
immunoblotting of mutant PV constructs. SK-HEP-1 cells were transfected
with expression vectors for PV-NLS-GFP or PV mutants with either one
(PV-NLS-CD-GFP) or two (PV-NLS-CDEF-GFP) mutated
Ca2+-binding sites. Total cellular proteins were separated
on SDS-PAGE and immunoblotted with a monoclonal anti-Myc antibody to
detect expression of the tagged ~40-kDa fusion proteins. Note that
expression of PV-NLS-CD-GFP is reduced compared with PV-NLS-GFP,
whereas the doubly defective mutant PV-NLS-CDEF-GFP was barely
expressed. B, nuclear localization of PV-NLS-CD-GFP.
Green indicates GFP construct, red indicates the
propidium iodide nuclear stain, and yellow indicates
co-localization of the two signals.
|
|
To examine the effect of PV-NLS-CD-GFP on Ca2+ transients,
transfected HepG2 cells were stimulated with ATP (10 µM)
and monitored as described for wild-type PV. No significant differences
were found in the ATP-induced rises in cytosolic fluorescence of
PV-NLS-CD-GFP-transfected cells and untransfected control cells (data
not shown; n = 50, p > 0.05). However,
ATP-induced increases in nuclear fluorescence were reduced in
PV-NLS-CD-GFP-transfected HepG2 cells, as compared with untransfected
control cells (Fig. 7; n = 50, p < 0.01), although to a lesser extent than in
PV-NLS-GFP-transfected cells (Fig. 7; n = 44, p < 0.001). These results thus indicate that the
mutant PV-NLS-CD-GFP exhibits a reduced ability to buffer
Ca2+ as compared with that of wild-type parvalbumin.
Therefore, this mutant PV protein was used to determine whether the
observed effects of PV expression are solely due to its
Ca2+ binding properties.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 7.
PV-NLS-CD-GFP exhibits weakened
Ca buffering capacity. HepG2 cells expressing
wild-type PV-NLS-GFP or the mutant PV-NLS-CD-GFP construct along with
untransfected controls were loaded with rhod-2 and stimulated with ATP
(10 µM). The changes of rhod-2 fluorescence in the
cytosolic and nuclear compartment were monitored using time lapse
confocal microscopy. A, scatter plots of increase in nuclear
versus cytosolic rhod-2 fluorescence. Each data point
represents the increases in rhod-2 fluorescence in the cytosolic and
nuclear compartment from an individual cell. The solid line
is the linear regression curve for these data, whereas the two
dashed lines surrounding the regression line define the 95%
confidence interval. B, graphical representation of the
slopes from the regression analyses. The slopes for the individual
regression curves are 0.63 ± 0.03 (n = 94),
0.29 ± 0.04 (n = 44), and 0.50 ± 0.06 (n = 50) for control, PV-NLS-GFP, and PV-NLS-CD-GFP,
respectively. The slope for the PV mutant is decreased by 30% from
pair-matched controls, whereas the slope for wild-type PV is decreased
by half. *, p < 0.05.
|
|
A Ca2+-binding Deficient Mutant of Parvalbumin Targeted
to the Nucleus Fails to Block EGF-mediated Elk-1
Transactivation--
To demonstrate that the inhibitory effects of
PV-NLS-GFP on EGF-mediated Elk-1 transactivation were due specifically
to the ability of PV to buffer Ca2+, we used the
Ca2+-binding deficient mutant of PV. Because EGF induced
Elk-1 transactivation by only 2-fold in HepG2 cells (Figs. 4 and 5), we
also examined the magnitude of EGF-induced Elk-1 transactivation in
human embryonic kidney 293 cells. We first examined nuclear and
cytosolic Ca2+ signaling in 293 cells following EGF
stimulation. Fura-2 ratio imaging of 293 cells revealed that both
nuclear and cytosolic Ca2+ levels are increased by EGF
(Fig. 8A). Second, EGF-induced
Elk-1 transactivation was substantially more robust than that of HepG2 cells, resulting in a 6-7-fold level of Elk-1 transactivation as
compared with controls (Fig. 8C). Thus, 293 cells appeared appropriate for our analysis of the effects of PV-NLS-GFP and PV-NLS-CD-GFP on EGF regulation of Elk-1.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
EGF-induced increase in
Ca but not Ca is required for
Elk-1 transactivation in 293 cells. A, EGF increases
Ca2+ both in the nucleus and cytosol of 293 cells. 293 cells loaded with fura-2 were stimulated with EGF (50-60 ng/ml), and
the EGF-induced Ca2+ responses in the nuclear and cytosolic
compartment were monitored by epifluorescence microscopy ratio imaging.
The data shown are representative results from >10 cells.
B, dose-response analysis of PV-NLS-GFP and PV-NLS-CD-GFP
protein expression. 293 cells were transfected either with PV-NLS-GFP
or PV-NLS-CD-GFP using the indicated amounts of cDNA. The cell
lysates were prepared and immunoblotted with anti-Myc antibodies. Note
that the expression of PV-NLS-CD-GFP is ~2-fold lower than
PV-NLS-GFP. C, 293 cells were transfected with the indicated
PV expression plasmids. The amount of PV-NLS-CD-GFP cDNA was
~2-fold higher than PV-NLS-GFP to obtain similar expression levels.
293 cells were rendered quiescent and then restimulated with EGF (10 ng/ml) for 5 h. The data represent the normalized luciferase to
-galactosidase units as a fold change relative to the unstimulated
vector control. These data represent the means ± S.E. of five
separate experiments performed in triplicate. The asterisk
indicates a significant difference (p < 0.05) compared
with EGF-stimulated GFP control.
|
|
Because the steady-state expression level of PV-NLS-CD-GFP was lower
than that of PV-NLS-GFP (Fig. 6A), we performed a titration with increasing amounts of these expression vectors. This permitted us
to use appropriate levels of cDNA for transfections to achieve comparable levels of protein expression. As shown in Fig.
8B, a comparable level of expression of PV-NLS-GFP to
PV-NLS-CD-GFP was achieved at a ratio of ~1 to 2 for PV-NLS-GFP to
PV-NLS-CD-GFP, respectively. 293 cells were transiently transfected
using these ratios of PV-NLS-GFP and PV-NLS-CD-GFP along with
PV-NES-GFP, Elkc, 5XGAL4-Luc, and a -galactosidase control. Although
EGF stimulation of 293 cells expressing GFP resulted in a 6-fold
activation of Elk-1, expression of PV-NLS-GFP reduced this to a 3-fold
Elk-1 transactivation (Fig. 8C). This represents an
inhibition by ~50% relative to the GFP-transfected controls
(p < 0.05). In contrast, expression of PV-NLS-CD-GFP
failed to inhibit EGF-stimulated Elk-1 transactivation relative to that
of GFP vector control (p > 0.05). These data
demonstrate that inhibition of Elk-1 transactivation by PV in the
nucleus is solely due to the ability of PV to buffer Ca2+.
Finally, as with HepG2 cells, expression of PV-NES-GFP in 293 cells
also failed to inhibit EGF-induced Elk-1 transactivation (Fig.
8C; p > 0.05). Taken together, these data
provide strong evidence that nuclear rather than cytosolic
Ca2+ is required to achieve maximal EGF-induced Elk-1 transactivation.
EGF-induced Activation and Translocation of ERK Is Not Affected by
Buffering Nuclear Ca2+--
Having demonstrated that
EGF-induced Elk-1 transactivation is dependent upon nuclear
Ca2+, we asked whether this inhibitory effect was due to
the inability of EGF to induce ERK activation and/or perturb ERK
translocation to the nucleus. To determine the effects of buffering
nuclear Ca2+ on EGF-induced ERK activation and
translocation to the nucleus, 293 cells were transiently transfected
with HA-tagged ERK2 and either GFP, PV-NLS-GFP, PV-NLS-CD-GFP, or
PV-NES-GFP. Following serum starvation, these transfected 293 cells
were stimulated with EGF (10 ng/ml) for 30 min, 1 h, or 2 h
and the levels of phospho-ERK2 were assessed. As shown in Fig.
9A, neither expression of
PV-NLS-GFP nor expression of PV-NES-GFP affected the level of
EGF-induced phospho-ERK2. Expression of PV-NLS-CD-GFP also did not
affect EGF-induced ERK2 phosphorylation (Fig. 9A).
Immunoblotting lysates prepared from these transfectants for ERK2 or PV
demonstrated that equal levels of both ERK2 and PV were expressed (Fig.
9A, middle and bottom panels).
These results suggest that the catalytic activity of ERK is unaffected
by buffering either nuclear or cytosolic Ca2+
independently.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 9.
PV-NLS-GFP does not affect EGF-induced ERK
phosphorylation or nuclear translocation of phospho-ERK2.
A, HA-tagged ERK2 was transfected into 293 cells along with
either GFP, PV-NLS-GFP, PV-NES-GFP, or PV-NLS-CD-GFP. Transfected 293 cells were rendered quiescent for 24 h and then restimulated with
EGF (10 ng/ml). The cell lysates were prepared at the indicated times.
HA-ERK2 was immunoprecipitated (IP) using an anti-HA
antibody, and these immune complexes were separated by SDS-PAGE and
analyzed by immunoblotting with anti-phospho-ERK antibodies (top
panel). This immunoblot was reprobed with anti-ERK antibodies
(middle panel). PV expression levels were confirmed by
immunoblotting with anti-Myc (9E10) antibodies (bottom
panel). B, EGF-induced ERK translocation can occur in
the presence of PV-NLS-GFP. 293 cells were co-transfected with
PV-NLS-GFP and HA-ERK2. The cells were either left unstimulated or
treated with EGF (100 ng/ml) for 10-15 min. Co-localization of
PV-NLS-GFP (green), total HA-tagged ERK (red),
and phospho-ERK (blue) was visualized by confocal
immunofluorescence using a monoclonal anti-HA and polyclonal
anti-phospho-ERK antibody, respectively. Nuclear labeling of all three
fluorophores (white) is seen in cells stimulated with
EGF.
|
|
To establish whether expression of PV-NLS-GFP inhibited Elk-1
transactivation by preventing translocation of ERK to the nucleus, we
determined the subcellular localization of ERK2 by confocal immunofluorescence. 293 cells were co-transfected with PV-NLS-GFP and
HA-ERK2 and were either left unstimulated or stimulated with EGF for
10-15 min. The localization of ERK2 and phospho-ERK was visualized
using anti-ERK and anti-phospho-ERK antibodies. In unstimulated 293 cells expressing PV-NLS-GFP, ERK2 was initially excluded from the
nucleus, and subsequently a fraction of ERK2 translocated to the
nucleus following EGF stimulation (Fig. 9B). Consistent with
our biochemical analysis, EGF-induced pERK was not inhibited by the
expression of PV-NLS-GFP. Moreover, pERK2 was found predominantly
within the nucleus of these cells. These data suggest that the
inhibitory effect of PV-NLS-GFP on Elk-1 transactivation does not occur
by affecting either the phosphorylation/activation or subcellular
localization of ERK in response to EGF.
EGF-induced Phosphorylation and Nuclear Localization of Elk-1 Is
Not Affected by Buffering Nuclear
Ca2+--
Phosphorylation of Elk-1 on
Ser383/Ser389 is a key post-translational
modification that regulates Elk-1 DNA binding and subsequently its
transcriptional activity (31). Therefore, we hypothesized that the
inhibitory actions of PV-NLS-GFP on EGF-induced Elk-1 transactivation
were due to the attenuation of Elk-1 phosphorylation. As shown in Fig.
10A, transient transfection
of FLAG-tagged Elk-1 followed by stimulation with EGF did not inhibit
its ability to become phosphorylated at Ser383 when either
PV-NLS-GFP or PV-NES-GFP was co-expressed. Again, as expected, the
Ca2+-deficient binding mutant did not show any effect on
EGF-induced Elk-1 phosphorylation (Fig. 10A). Both Elk-1 and
PV were expressed at equivalent levels in these transfections (Fig.
10A, middle and bottom panels).
Finally, we determined whether expressing PV-NLS-GFP affected the
nuclear localization of either Elk-1 itself or its phosphorylated form
(Fig. 10B). 293 cells were transiently transfected with
FLAG-Elk-1 and PV-NLS-GFP and either left unstimulated or stimulated
with EGF. Elk-1 was localized to the nucleus in both the
unphosphorylated and phosphorylated forms. This subcellular localization was not altered in cells expressing PV-NLS-GFP (Fig. 10B). Thus, phosphorylation of Elk-1 is not sufficient for
its activation. Moreover, EGF-induced activation of Elk-1 depends not
only on Elk-1 phosphorylation but also upon
Ca .

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 10.
PV-NLS-GFP does not affect EGF-induced Elk-1
phosphorylation or localization. A, PV-NLS-GFP or
PV-NES-GFP do not affect EGF-induced Elk phosphorylation. FLAG-tagged
Elk-1 was transfected into 293 cells along with GFP vector control,
PV-NLS-GFP, PV-NES-GFP, and PV-NLS-CD-GFP. Following serum deprivation
for 24 h, quiescent 293 cells were stimulated with EGF (10 ng/ml),
and whole cell lysates were prepared at the indicated times and
separated by SDS-PAGE. The proteins were analyzed by immunoblotting
with either anti-phospho (383)-Elk-1 (top panel) or with
anti-FLAG (middle panel) antibodies. PV expression levels
were confirmed by immunoblotting with anti-Myc (9E10) antibodies
(bottom panel). Lane U, represents lysates
prepared from untransfected 293 cells as a control. B,
PV-NLS-GFP does not alter Elk-1 localization. 293 cells were
co-transfected with PV-NLS-GFP and an expression vector for FLAG-Elk-1.
The cells were either left unstimulated or treated with EGF for 10-15
min. Co-localization of PV-NLS-GFP (green), total
FLAG-tagged Elk-1 (red), and phospho-Elk-1 (blue)
was visualized by confocal immunofluorescence using a monoclonal
anti-FLAG and polyclonal anti-phospho-Elk-1 antibodies, respectively.
Nuclear labeling of all three fluorophores (white) is seen
in cells stimulated with EGF.
|
|
Additional Evidence That Elk-1 Phosphorylation Is Not Sufficient to
Activate Elk-1 Transcription--
Our data imply that
Ca is required for EGF-mediated
transactivation of Elk-1. To test whether Ca is also sufficient, we
investigated whether ionomycin could induce Elk-1 transactivation.
Treatment of 293 cells with ionomycin increased both
Ca and
Ca (Fig.
11, A and B) and
also resulted in the phosphorylation of Elk-1 (Fig. 11C). In
contrast to EGF, ionomycin failed to stimulate transactivation of Elk-1 (Fig. 11D). Similar results were also observed using HepG2
cells (data not shown). Taken together, these data show that both
Ca and Elk-1 phosphorylation are
necessary but not sufficient to induce EGF-mediated transactivation of
Elk-1.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 11.
Uncoupling of Elk-1 phosphorylation from
Elk-1 transactivation. A and B, ionomycin
induces Ca2+ signals in both the nucleus and cytosol of 293 cells. 293 cells loaded with fluo-4 were stimulated with 0.25 µM ionomycin and Ca2+ in both the nuclear and
cytosolic compartment were monitored by confocal microscopy.
Pseudocolor images of changes in Ca
and Ca in 293 cells during
stimulation with ionomycin are shown in A. The time course
of changes in Ca and
Ca in a representative 293 cell
during stimulation with ionomycin is shown in B. C, 293 cells were treated with ionomycin (0.25 µM), and at the indicated times lysates were prepared and
separated by SDS-PAGE. The proteins were transferred to Immobilon P
membranes and immunoblotted with anti-phospho-Elk-1 antibodies. As a
control this membrane was reprobed using anti-FLAG antibodies to detect
for the expression of FLAG-Elk-1. D, 293 cells were
transfected with Elk-1, 5XGAL4 luciferase, and -galactosidase.
Following serum starvation, 293 cells were left unstimulated or were
stimulated with either ionomycin (0.25 µM) or EGF (10 ng/ml) for 5 h. Luciferase activities were normalized to
-galactosidase. These data represent the means ± S.E. of three
separate experiments performed in triplicate.
|
|
 |
DISCUSSION |
Previous studies have suggested that Ca2+ signals in
the nucleus can be regulated independently of Ca2+ signals
in the cytosol (17, 63-66). In addition, several
Ca2+-dependent nuclear functions have been
proposed, including apoptosis (67), nucleocytoplasmic transport of
proteins (68, 69), and gene transcription (21, 22). However, the
ability to study the effects of spatially distinct Ca2+
signaling has been technically challenging. Some investigators have
employed single cell nuclear microinjection of a nondiffusible Ca2+ buffer to block increases in
Ca but not
Ca (21, 22). Although this approach
has provided valuable information regarding the role of
Ca , this technique examines only
single cells and thus is not conducive to performing extensive biochemical studies. The current report overcomes this limitation by
using targeted expression of the Ca2+-binding protein PV to
selectively inhibit Ca2+ signaling in either the nucleus or
cytosol. This strategy therefore facilitates the study of the role of
subcellular Ca2+ signals in a variety of biological processes.
PV is a high affinity Ca2+-binding protein of the EF hand
type with a ~103 higher affinity for Ca2+
(Kd = 2.4 × 107
M 1) than Mg2+
(Kd = 2.9 × 104
M 1) (70, 71). The metal-ion binding
properties and crystallographic structure of PV have been described in
detail (48, 61, 72). It is found at its highest concentration in
quickly contracting skeletal muscle (70, 73), nervous tissue (74),
kidney (75), testis (76), and endocrine glands (77). PV has been used
previously as a tool to manipulate the effects of Ca2+ in a
variety of biological processes (54, 55, 78-81). The Ca2+
buffering capacity of PV is thought to facilitate the relaxation of
fast muscle. Expression of PV in normal and regenerating rat soleus
muscle significantly shortens twitch half-relaxation time in a
dose-dependent manner (78). PV gene transfer also enhances mechanical relaxation in cardiac myocytes (79). This effect is seen in
the intact heart as well and has been proposed as a strategy to improve
certain types of heart failure (80). A study of a PV knockout mouse has
shown that the Ca2+ buffering action of PV also is
important for the regulation of short term synaptic plasticity in
gamma-amino butyric acid-responsive neurons (81). Furthermore,
ectopic expression of PV in nonmuscle cell types attenuates cell cycle
progression (54, 55). However, the current work is the first
demonstration that targeted expression of PV can be used to examine the
effects of Ca2+ in distinct subcellular regions.
EGF-mediated increases in Ca have
been suggested to mediate processes such as mitogenesis, proliferation, and gene expression (82-87). However, the role specifically for Ca in EGF signaling has yet to be defined. We show that in response to EGF, a GAL4 DNA-binding
domain/carboxyl terminus Elk-1 chimera was inhibited in its ability to
direct transcription from a heterologous GAL4 DNA-binding element when PV was targeted to the nucleus. In contrast, expression of PV in the
cytosol did not affect EGF-induced Elk-1 transactivation (Figs. 5 and
8). These data suggest that Ca but
not Ca is involved in
Elk-1-mediated regulation by EGF. However, this conclusion is
predicated on the assumption that PV exerts its effects exclusively
through buffering Ca2+. We substantiated this in two ways.
First, we demonstrated that EGF-mediated transactivation of Elk-1 was
indeed Ca2+-dependent through the use of the
intracellular Ca2+ chelator BAPTA-AM (Fig. 4). Second, we
generated a mutant within one of the two EF hands of PV, rendering PV
deficient in its Ca2+ binding efficiency. When this PV
mutant was expressed in the nucleus, at levels equivalent to that of
the wild-type form of PV, EGF retained its ability to transactivate
Elk-1 (Fig. 8). Thus, our findings provide strong evidence that the
inhibitory effect of PV on EGF-induced Elk-1 transactivation is a
direct consequence of the ability of PV to buffer
Ca . These data furthermore provide
evidence for the specificity of PV as a tool for buffering
Ca2+ and are the first to implicate the possibility that
Ca signals participate in
EGF-mediated transcriptional regulation.
The activation of Elk-1 is dependent upon phosphorylation within its
carboxyl terminus at several residues by members of the MAPK family,
including the ERKs (24, 33). Phosphorylation of Elk-1 then enhances its
DNA binding through the serum response element, thereby promoting
transcription (88). To provide a mechanistic basis for our finding that
Ca is required for EGF-induced
Elk-1 transactivation, we examined the effects of EGF on ERK activation
in 293 cells expressing PV in the nucleus or cytosol. Interestingly,
expression of PV in the nucleus of 293 cells failed to suppress
EGF-induced ERK activation. The ability of ERK to translocate to the
nucleus also was unaffected by expression of PV in the nucleus (Fig.
9). These data suggested that the inability of EGF to induce maximal
Elk-1 transactivation is independent of ERK. Several reports have
described ERK-independent mechanisms for Elk-1 regulation (89-91);
therefore we directly assessed the phosphorylation status of Elk-1.
Surprisingly, Elk-1 was phosphorylated and localized to the nucleus
following EGF stimulation, regardless of whether cells expressed PV in
the nucleus. Thus, our data have identified that Elk-1 phosphorylation,
specifically at Ser383, can be dissociated from its
transactivation following EGF stimulation. Additional evidence that
this dissociation can occur was obtained by demonstrating that
ionomycin also was able to phosphorylate Elk-1, without inducing Elk-1
transactivation. Collectively, these data suggest that
Ca and Elk-1 phosphorylation both
are necessary but not sufficient to mediate Elk-1 transcriptional activation by EGF. It is possible that EGF provides an additional signal not provided for by ionomycin that also is essential to initiate
Elk-1 transactivation. It is important to note that our studies using
this Elk-1-GAL4 chimera may not necessarily reflect the behavior of the
native Elk-1 transcription factor in context with its cognate serum
response element. Several studies have provided evidence to support the
idea that phosphorylation of the transcriptional activation domain
induces critical conformational changes in Elk-1 that regulate its
transcriptional activity (88). Although transcription factors are
modular in their structure, the effects of phosphorylation of Elk-1 may
not be faithfully reflected in the Elk-1-GAL4 chimera used in these
experiments. On the other hand, it is also reasonable to propose that
additional EGF-regulated and Ca2+-dependent
co-factors interact with Elk-1 to induce maximal transcriptional activation.
The complexity of the EGF-Elk-1 signaling pathway is compounded by the
fact that multiple signaling pathways converge on Elk-1. For example,
Elk-1 is positively regulated by Ca2+ via the MAPKs and
CaM-KII/IV pathways and negatively regulated by calcineurin (42, 44,
45). Thus, Elk-1 may be regulated directly via these
Ca2+-dependent kinases and phosphatases, each
of which has been found in the nucleus. It is likely that the balance
among these opposing pathways will likely set the net state of Elk-1
responsiveness. Several reports have described
MAPK-dependent and -independent pathways for the regulation
of Elk-1 (24, 62, 89-91). Finally, it has also been suggested that
both the kinetics and magnitude of the Ca2+ signal might be
involved in the control of gene expression (10-12). Nuclear expression
of PV may perturb these more subtle kinetic regulatory events of
Ca2+ that ultimately could lead to attenuation of
EGF-induced Elk-1 transactivation.
Our report describes a powerful tool in which to perturb
Ca2+ signals distinctly within the nucleus and cytosol.
This approach is amenable to the application of standard biochemical
approaches, which has allowed us to reveal new insights into the role
of nuclear Ca2+ in EGF-mediated regulation of Elk-1.
Although we found that Ca is
necessary for transactivation of Elk-1, additional work will be needed
to determine how Ca links Elk-1
phosphorylation to its transactivation.
 |
ACKNOWLEDGEMENTS |
We thank the members of the Bennett,
Nathanson, and Ehrlich labs and Drs. Peter Koulen, Paul Lombroso, and
Andrew Sharrocks for helpful comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported by grants from the National
Institutes of Health and the American Heart Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a grant from the American Liver Foundation and
Deutsche Forschungsgemeinschaft.
§§
To whom correspondence should be addressed: Yale University
School of Medicine, Dept. of Pharmacology, SHM B230, 333 Cedar St., New
Haven, CT 06520-8066. Tel.: 203-737-2441; Fax: 203-785-4395; E-mail: anton.bennett@yale.edu.
Published, JBC Papers in Press, April 23, 2002, DOI 10.1074/jbc.M203002200
 |
ABBREVIATIONS |
The abbreviations used are:
Ca , nuclear free calcium;
Ca , cytosolic free calcium;
MAPK, mitogen-activated protein kinase;
MKK, MAPK kinase;
EGF, epidermal
growth factor;
ERK, extracellular regulated kinase;
PV, parvalbumin;
NES, nuclear exclusion signal;
NLS, nuclear localization signal;
GFP, green fluorescent protein;
AM, acetoxymethyl;
HA, hemagglutinin;
BAPTA, bis(2-aminophenyl)ethyleneglycol-N,N,N',N'-tetraacetic
acid.
 |
REFERENCES |
| 1.
|
Berridge, M. J.
(1993)
Nature
361,
315-325[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Clapham, D. E.
(1995)
Cell
80,
259-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Gomez, T. M.,
and Spitzer, N. C.
(1999)
Nature
397,
350-355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Ito, K.,
Miyashita, Y.,
and Kasai, H.
(1997)
EMBO J.
16,
242-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Shen, S. S.
(1995)
Curr. Top. Dev. Biol.
30,
63-101[Medline]
[Order article via Infotrieve]
|
| 6.
|
Szalai, G.,
Krishnamurthy, R.,
and Hajnoczky, G.
(1999)
EMBO J.
18,
6349-6361[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Santella, L.
(1998)
Biochem. Biophys. Res. Commun.
244,
317-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Berridge, M. J.,
Bootman, M. D.,
and Lipp, P.
(1998)
Nature
395,
645-648[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Webb, S. E.,
and Miller, A. L.
(2000)
Bioessays
22,
113-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Li, W.,
Llopis, J.,
Whitney, M.,
Zlokarnik, G.,
and Tsien, R. Y.
(1998)
Nature
392,
936-941[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Dolmetsch, R. E., Xu, K.,
and Lewis, R. S.
(1998)
Nature
392,
933-936[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Dolmetsch, R. E.,
Lewis, R. S.,
Goodnow, C. C.,
and Healy, J. I.
(1997)
Nature
386,
855-858[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Zheng, J. Q.
(2000)
Nature
403,
89-93[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ginty, D. D.
(1997)
Neuron
18,
183-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Johenning, F. W.,
Zochowski, M.,
Conway, S. J.,
Holmes, A. B.,
Koulen, P.,
and Ehrlich, B. E.
(2002)
J. Neurosci.
22,
5344-5353[Abstract/Free Full Text]
|
| 16.
|
Humbert, J. P.,
Matter, N.,
Artault, J. C.,
Koppler, P.,
and Malviya, A. N.
(1996)
J. Biol. Chem.
271,
478-485[Abstract/Free Full Text]
|
| 17.
|
Gerasimenko, O. V.,
Gerasimenko, J. V.,
Tepikin, A. V.,
and Petersen, O. H.
(1995)
Cell
80,
439-444[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Divecha, N.,
Banfic, H.,
and Irvine, R. F.
(1991)
EMBO J.
10,
3207-3214[Medline]
[Order article via Infotrieve]
|
| 19.
|
Lanini, L.,
Bachs, O.,
and Carafoli, E.
(1992)
J. Biol. Chem.
267,
11548-11552[Abstract/Free Full Text]
|
| 20.
|
Nicotera, P.,
McConkey, D. J.,
Jones, D. P.,
and Orrenius, S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
453-457[Abstract/Free Full Text]
|
| 21.
|
Hardingham, G. E.,
Chawla, S.,
Johnson, C. M.,
and Bading, H.
(1997)
Nature
385,
260-265[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Chawla, S.,
Hardingham, G. E.,
Quinn, D. R.,
and Bading, H.
(1998)
Science
281,
1505-1509[Abstract/Free Full Text]
|
| 23.
|
Sharrocks, A. D.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
827-837[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Treisman, R.
(1996)
Curr. Opin. Cell Biol.
8,
205-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Khokhlatchev, A. V.,
Canagarajah, B.,
Wilsbacher, J.,
Robinson, M.,
Atkinson, M.,
Goldsmith, E.,
and Cobb, M. H.
(1998)
Cell
93,
605-615[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Cobb, M. H.
(1999)
Prog. Biophys. Mol. Biol.
71,
479-500[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Davis, R. J.
(1993)
J. Biol. Chem.
268,
14553-14556[Free Full Text]
|
| 28.
|
Ip, Y. T.,
and Davis, R. J.
(1998)
Curr. Opin. Cell Biol.
10,
205-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Xia, Z.,
Dickens, M.,
Raingeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331[Abstract/Free Full Text]
|
| 30.
|
Chen, R. H.,
Sarnecki, C.,
and Blenis, J.
(1992)
Mol. Cell. Biol.
12,
915-927[Abstract/Free Full Text]
|
| 31.
|
Yordy, J. S.,
and Muise-Helmericks, R. C.
(2000)
Oncogene
19,
6503-6513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Marais, R.,
Wynne, J.,
and Treisman, R.
(1993)
Cell
73,
381-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Treisman, R.
(1994)
Curr. Opin. Genet. Dev.
4,
96-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Kamat, A.,
and Carpenter, G.
(1997)
Cytokine Growth Factor Rev.
8,
109-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Nojiri, S.,
and Hoek, J. B.
(2000)
Hepatology
32,
947-957[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Hepler, J. R.,
Nakahata, N.,
Lovenberg, T. W.,
DiGuiseppi, J.,
Herman, B.,
Earp, H. S.,
and Harden, T. K.
(1987)
J. Biol. Chem.
262,
2951-2956[Abstract/Free Full Text]
|
| 37.
|
Maloney, J. A.,
Tsygankova, O. M.,
Yang, L., Li, Q.,
Szot, A.,
Baysal, K.,
and Williamson, J. R.
(1999)
Am. J. Physiol.
276,
C221-C230[Medline]
[Order article via Infotrieve]
|
| 38.
|
Lev, S.,
Moreno, H.,
Martinez, R.,
Canoll, P.,
Peles, E.,
Musacchio, J. M.,
Plowman, G. D.,
Rudy, B.,
and Schlessinger, J.
(1995)
Nature
376,
737-745[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Anborgh, P. H.,
Qian, X.,
Papageorge, A. G.,
Vass, W. C.,
DeClue, J. E.,
and Lowy, D. R.
(1999)
Mol. Cell. Biol.
19,
4611-4622[Abstract/Free Full Text]
|
| 40.
|
Means, A. R.
(2000)
Mol. Endocrinol.
14,
4-13[Free Full Text]
|
| 41.
|
Bernal-Mizrachi, E.,
Wen, W.,
Srinivasan, S.,
Klenk, A.,
Cohen, D.,
and Permutt, M. A.
(2001)
Am. J. Physiol.
281,
E1286-E1299
|
| 42.
|
Enslen, H.,
Tokumitsu, H.,
Stork, P. J.,
Davis, R. J.,
and Soderling, T. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10803-10808[Abstract/Free Full Text]
|
| 43.
|
Cruzalegui, F. H.,
and Bading, H.
(2000)
Cell. Mol. Life Sci.
57,
402-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Sugimoto, T.,
Stewart, S.,
and Guan, K. L.
(1997)
J. Biol. Chem.
272,
29415-29418[Abstract/Free Full Text]
|
| 45.
|
Tian, J.,
and Karin, M.
(1999)
J. Biol. Chem.
274,
15173-15180[Abstract/Free Full Text]
|
| 46.
|
Fukuda, M.,
Gotoh, I.,
Adachi, M.,
Gotoh, Y.,
and Nishida, E.
(1997)
J. Biol. Chem.
272,
32642-32648[Abstract/Free Full Text]
|
| 47.
|
Adachi, M.,
Fukuda, M.,
and Nishida, E.
(2000)
J. Cell Biol.
148,
849-856[Abstract/Free Full Text]
|
| 48.
|
Pauls, T. L.,
Durussel, I.,
Cox, J. A.,
Clark, I. D.,
Szabo, A. G.,
Gagne, S. M.,
Sykes, B. D.,
and Berchtold, M. W.
(1993)
J. Biol. Chem.
268,
20897-20903[Abstract/Free Full Text]
|
| 49.
|
Leite, M. F.,
Burgstahler, A. D.,
and Nathanson, M. H.
(2002)
Gastroenterology
122,
415-427[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 51.
|
Xu, C.,
Zipfel, W.,
Shear, J. B.,
Williams, R. M.,
and Webb, W. W.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10763-10768[Abstract/Free Full Text]
|
| 52.
|
Schlosser, S. F.,
Burgstahler, A. D.,
and Nathanson, M. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9948-9953[Abstract/Free Full Text]
|
| 53.
|
Minta, A.,
Kao, J. P.,
and Tsien, R. Y.
(1989)
J. Biol. Chem.
264,
8171-8178[Abstract/Free Full Text]
|
| 54.
|
Andressen, C.,
Gotzos, V.,
Berchtold, M. W.,
Pauls, T. L.,
Schwaller, B.,
Fellay, B.,
and Celio, M. R.
(1995)
Exp. Cell Res.
219,
420-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Rasmussen, C. D.,
and Means, A. R.
(1989)
Mol. Endocrinol.
3,
588-596[Abstract/Free Full Text]
|
| 56.
|
Fischer-Fantuizz, L.,
and Vesco, C.
(1988)
Mol. Cell. Biol.
8,
5495-5503[Abstract/Free Full Text]
|
| 57.
|
Dubyak, G. R.,
and el-Moatassim, C.
(1993)
Am. J. Physiol.
265,
C577-C606[Medline]
[Order article via Infotrieve]
|
| 58.
|
Burnstock, G.
(1997)
Neuropharmacology
36,
1127-1139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Tanaka, Y.,
Hayashi, N.,
Kaneko, A.,
Ito, T.,
Miyoshi, E.,
Sasaki, Y.,
Fusamoto, H.,
and Kamada, T.
(1992)
Hepatology
16,
479-486[Medline]
[Order article via Infotrieve]
|
| 60.
|
Himpens, B., De,
Smedt, H.,
and Casteels, R.
(1993)
Am. J. Physiol.
265,
C966-C975[Medline]
[Order article via Infotrieve]
|
| 61.
|
Pauls, T. L.,
Durussel, I.,
Berchtold, M. W.,
and Cox, J. A.
(1994)
Biochemistry
33,
10393-10400[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Fukuda, K.,
Tsuchihara, K.,
Hijikata, M.,
Nishiguchi, S.,
Kuroki, T.,
and Shimotohno, K.
(2001)
Hepatology
33,
159-165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Santella, L.,
and Carafoli, E.
(1997)
FASEB J.
11,
1091-1109[Abstract]
|
| 64.
|
Malviya, A. N.,
and Rogue, P. J.
(1998)
Cell
92,
17-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Santella, L.,
and Kyozuka, K.
(1997)
Cell Calcium
22,
11-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Hennager, D. J.,
Welsh, M. J.,
and DeLisle, S.
(1995)
J. Biol. Chem.
270,
4959-4962[Abstract/Free Full Text]
|
| 67.
|
Nicotera, P.,
and Rossi, A. D.
(1994)
Mol. Cell. Biochem.
135,
89-98[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Stehno-Bittel, L.,
Perez-Terzic, C.,
and Clapham, D. E.
(1995)
Science
270,
1835-1838[Abstract/Free Full Text]
|
| 69.
|
Lee, M. A.,
Dunn, R. C.,
Clapham, D. E.,
and Stehno-Bittel, L.
(1998)
Cell Calcium
23,
91-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Heizmann, C. W.
(1984)
Experientia
40,
910-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Pauls, T. L.,
Cox, J. A.,
and Berchtold, M. W.
(1996)
Biochim. Biophys. Acta
1306,
39-54[Medline]
[Order article via Infotrieve]
|
| 72.
|
Kretsinger, R. H.
(1980)
CRC Crit. Rev. Biochem.
8,
119-174[Medline]
[Order article via Infotrieve]
|
| 73.
|
Berchtold, M. W.
(1989)
Biochim. Biophys. Acta
1009,
201-215[Medline]
[Order article via Infotrieve]
|
| 74.
|
Celio, M. R.
(1986)
Science
231,
995-997[Abstract/Free Full Text]
|
| 75.
|
Schneeberger, P. R.,
and Heizmann, C. W.
(1986)
FEBS Lett.
201,
51-56[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Kagi, U.,
Berchtold, M. W.,
and Heizmann, C. W.
(1987)
J. Biol. Chem.
262,
7314-7320[Abstract/Free Full Text]
|
| 77.
|
Endo, T.,
Takazawa, K.,
and Onaya, T.
(1985)
Endocrinology
117,
527-531[Abstract/Free Full Text]
|
| 78.
|
Muntener, M.,
Kaser, L.,
Weber, J.,
and Berchtold, M. W.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6504-6508[Abstract/Free Full Text]
|
| 79.
|
Wahr, P. A.,
Michele, D. E.,
and Metzger, J. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11982-11985[Abstract/Free Full Text]
|
| 80.
|
Szatkowski, M. L.,
Westfall, M. V.,
Gomez, C. A.,
Wahr, P. A.,
Michele, D. E.,
DelloRusso, C.,
Turner, I.,
Hong, K. E.,
Albayya, F. P.,
and Metzger, J. M.
(2001)
J. Clin. Invest.
107,
191-198[Medline]
[Order article via Infotrieve]
|
| 81.
|
Caillard, O.,
Moreno, H.,
Schwaller, B.,
Llano, I.,
Celio, M. R.,
and Marty, A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
13372-13377[Abstract/Free Full Text]
|
| 82.
|
Loza, J.,
Marzec, N.,
Simasko, S.,
and Dziak, R.
(1995)
Cell Calcium
17,
301-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 83.
|
Magni, M.,
Meldolesi, J.,
and Pandiella, A.
(1991)
J. Biol. Chem.
266,
6329-6335[Abstract/Free Full Text]
|
| 84.
|
Hill, T. D.,
Kindmark, H.,
and Boynton, A. L.
(1988)
J. Cell. Biochem.
38,
137-144[CrossRef][Medline]
[Order article via Infotrieve]
|
| 85.
|
Ichikawa, J.,
and Kiyohara, T.
(2001)
Cell Biochem. Funct.
19,
213-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Wagstaff, S. C.,
Bowler, W. B.,
Gallagher, J. A.,
and Hipskind, R. A.
(2000)
Carcinogenesis
21,
2175-2181[Abstract/Free Full Text]
|
| 87.
|
Lenormand, P.,
Pribnow, D.,
Rodland, K. D.,
and Magun, B. E.
(1992)
Mol. Cell. Biol.
12,
2793-2803[Abstract/Free Full Text]
|
| 88.
|
Yang, S. H.,
Shore, P.,
Willingham, N.,
Lakey, J. H.,
and Sharrocks, A. D.
(1999)
EMBO J.
18,
5666-5674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 89.
|
Gu, H.,
Pratt, J. C.,
Burakoff, S. J.,
and Neel, B. G.
(1998)
Mol. Cell
2,
729-740[CrossRef][Medline]
[Order article via Infotrieve]
|
| 90.
|
Zhao, C., Yu, D. H.,
Shen, R.,
and Feng, G. S.
(1999)
J. Biol. Chem.
274,
19649-19654[Abstract/Free Full Text]
|
| 91.
|
Sugimoto, T.,
Stewart, S.,
Han, M.,
and Guan, K. L.
(1998)
EMBO J.
17,
1717-1727[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. D. Bootman, C. Fearnley, I. Smyrnias, F. MacDonald, and H. L. Roderick
An update on nuclear calcium signalling
J. Cell Sci.,
July 15, 2009;
122(14):
2337 - 2350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Leuenroth and C. M. Crews
Triptolide-Induced Transcriptional Arrest Is Associated with Changes in Nuclear Substructure
Cancer Res.,
July 1, 2008;
68(13):
5257 - 5266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Gomes, M. A. Rodrigues, M. F. Leite, M. V. Gomez, P. Varnai, T. Balla, A. M. Bennett, and M. H. Nathanson
c-Met Must Translocate to the Nucleus to Initiate Calcium Signals
J. Biol. Chem.,
February 15, 2008;
283(7):
4344 - 4351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Harrisingh, Y. Wu, G. A. Lnenicka, and M. N. Nitabach
Intracellular Ca2+ Regulates Free-Running Circadian Clock Oscillation In Vivo
J. Neurosci.,
November 14, 2007;
27(46):
12489 - 12499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Rodrigues, D. A. Gomes, M. F. Leite, W. Grant, L. Zhang, W. Lam, Y.-C. Cheng, A. M. Bennett, and M. H. Nathanson
Nucleoplasmic Calcium Is Required for Cell Proliferation
J. Biol. Chem.,
June 8, 2007;
282(23):
17061 - 17068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Kruglov, P. R. A. V. Correa, G. Arora, J. Yu, M. H. Nathanson, and J. A. Dranoff
Molecular basis for calcium signaling in hepatic stellate cells
Am J Physiol Gastrointest Liver Physiol,
April 1, 2007;
292(4):
G975 - G982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Muller-Borer, W. E. Cascio, G. L. Esch, H.-S. Kim, W. B. Coleman, J. W. Grisham, P. A. W. Anderson, and N. N. Malouf
Mechanisms controlling the acquisition of a cardiac phenotype by liver stem cells
PNAS,
March 6, 2007;
104(10):
3877 - 3882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. O'Brien, D. A. Gomes, S. Sehgal, and M. H. Nathanson
Hormonal Regulation of Nuclear Permeability
J. Biol. Chem.,
February 9, 2007;
282(6):
4210 - 4217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Wamhoff, D. K. Bowles, and G. K. Owens
Excitation-Transcription Coupling in Arterial Smooth Muscle
Circ. Res.,
April 14, 2006;
98(7):
868 - 878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yang, S. A. Fox, J. L. Kirby, B. V. Troan, and B. T. Hinton
Putative Regulation of Expression of Members of the Ets Variant 4 Transcription Factor Family and Their Downstream Targets in the Rat Epididymis
Biol Reprod,
April 1, 2006;
74(4):
714 - 720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Estrada, P. Uhlen, and B. E. Ehrlich
Ca2+ oscillations induced by testosterone enhance neurite outgrowth
J. Cell Sci.,
February 15, 2006;
119(4):
733 - 743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Li, Z. Li, and D. B. Sacks
The Transcriptional Activity of Estrogen Receptor-{alpha} Is Dependent on Ca2+/Calmodulin
J. Biol. Chem.,
April 1, 2005;
280(13):
13097 - 13104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rieder, A. J. Tessier, X. T. Qiao, B. Madison, D. L. Gumucio, and J. L. Merchant
Helicobacter-induced Intestinal Metaplasia in the Stomach Correlates with Elk-1 and Serum Response Factor Induction of Villin
J. Biol. Chem.,
February 11, 2005;
280(6):
4906 - 4912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kolli, C. I. Zito, M. H. Mossink, E. A. C. Wiemer, and A. M. Bennett
The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling
J. Biol. Chem.,
July 9, 2004;
279(28):
29374 - 29385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Leite, E. C. Thrower, W. Echevarria, P. Koulen, K. Hirata, A. M. Bennett, B. E. Ehrlich, and M. H. Nathanson
Nuclear and cytosolic calcium are regulated independently
PNAS,
March 4, 2003;
100(5):
2975 - 2980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Dolmetsch
Excitation-Transcription Coupling: Signaling by Ion Channels to the Nucleus
Sci. Signal.,
January 21, 2003;
2003(166):
pe4 - pe4.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|